Indeed, according to Bruce Levine, a specialist in cancer gene therapies at the University of Pennsylvania, “there have been around 35,000 patients treated worldwide with CAR T therapies.” Thus, 19 cases of secondary cancer is only 0.05% of treated patients. “If there is a very small percentage of cancers that have been induced by CAR, I don’t want to trivialize it, but we do have to put that risk in context with 网页链接{conventional chemotherapy},” which 网页链接{has also been linked} to secondary cancers, Levine told BioSpace.$金斯瑞生物科技(01548)$ $金斯瑞生物科技(01548)$